Jazz Pharmaceuticals (JAZZ) FY2024 results: revenue $4.1 billion, up 6.1% on the year
Jazz Pharmaceuticals plc (JAZZ) reported revenue of $4.1 billion for fiscal 2024, the year ended 31 December 2024, up 6.1% on the year before. Net income was $560 million, up 35.0%, and diluted earnings per share $8.65. The figures are the company's own, from the 10-K it filed with the SEC on 26 February 2025.
Revenue
$4.1 billion
+6.1% on the year
FY2017FY2024
Operating margin
17.6%
15.1% a year earlier
FY2017FY2024
Net income
$560 million
+35.0% on the year
FY2017FY2024
Diluted EPS
$8.65
+41.8% on the year
FY2017FY2024
this yearthe year beforeHover a bar for its figure.
$ million except per share. Read moreFree cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Those four are arithmetic on the filed numbers; everything else is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and share counts are as they are.
Cash flow
$ million
FY2024
FY2023
FY2022
On the year
Last 8 years
Operating cash flow
1,396
1,092
1,272
+27.8%
Capital expenditure
38.1
24.0
29.0
+58.9%
Free cash flow
1,358
1,068
1,243
+27.1%
Free cash flow margin
33.4%
27.9%
34.0%
Cash from investing
-508
-163
-446
Cash from financing
20.5
-305
-529
Depreciation and amortisation
32.8
30.4
30.3
+7.9%
Share-based compensation
248
227
222
+9.3%
Buybacks
311
270
0.1
+15.4%
Diluted shares, weighted
66m
72m
63m
-8.4%
Shares outstanding at period end
61m
62m
63m
-2.6%
Balance sheet
$ million
FY2024
FY2023
FY2022
On the year
Last 8 years
Shareholders' equity
4,094
3,737
3,086
+9.5%
Debt
6,109
5,713
5,724
+6.9%
Operating lease liabilities
38.9
59.2
71.8
-34.3%
Finance lease liabilities
4.6
5.0
5.2
-9.5%
Other liabilities
1,766
1,879
1,948
-6.0%
Total liabilities and equity
12,012
11,393
10,835
+5.4%
Goodwill
1,716
1,753
1,693
-2.1%
Intangible assets
4,756
5,418
5,794
-12.2%
Securities held for sale or to maturity
2,993
1,626
881
+84.0%
Cash and equivalents
2,413
1,506
881
+60.2%
Receivables
717
706
651
+1.6%
Inventory
480
597
714
-19.5%
Other assets
n/a
n/a
220
Total assets
12,012
11,393
10,835
+5.4%
10-K for the year ended 31 December 2024, filed 26 February 2025: the filing.